In the present study, we found that chronic administration of bevacizumab, a monoclonal anti-VEGF antibody used for GBM, induced expression of proinflammatory cytokines with massive infiltration of immune cells in GBM xenografts. This evidence concerns the gene VEGFA and glioblastoma.